Sign In
Section Navigation
Common TitleOCTANE A5208
Official Title Optimal Combination Therapy After Nevirapine Exposure
Phase Phase III
ClinicalTrials.gov NCT00089505
Treatments
Nevirapine
Nevirapine Viramune

Nevirapine

Tradename:ViramuneOther Names:NVPClass:Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
Categories Resistance/Virological FailurePregnancy/WomenPharmacologyAdverse EffectsTreatment-Experienced
Funding
Non-IndustryNational Institute of Allergy and Infectious Diseases (NIAID)
References
  • Boltz VF, Bao Y, Lockman S, et al. Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP. J Infect Dis. 2014;209:703-10.
    [PubMed Abstract]
  • Dong BJ, Zheng Y, Hughes MD, et al. Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women. AIDS. 2012;26:833-41.
    [PubMed Abstract]
  • Lockman S, Hughes M, Sawe F, et al. Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. PLoS Med. 2012;9:e1001236.
    [PubMed Abstract]
  • Lockman S, Hughes MD, McIntyre J, et al. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med. 2010;363:1499-509.
    [PubMed Abstract]
  • Mwafongo A, Nkanaunena K, Zheng Y, et al. Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine. AIDS. 2014;28:1135-42.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.